Information on EC 3.2.1.35 - hyaluronoglucosaminidase

New: Word Map on EC 3.2.1.35
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Mark a special word or phrase in this record:
Search Reference ID:
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results (more...)
Include results (AMENDA + additional results, but less precise; more...)

The enzyme appears in viruses and cellular organisms

EC NUMBER
COMMENTARY hide
3.2.1.35
-
RECOMMENDED NAME
GeneOntology No.
hyaluronoglucosaminidase
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Random hydrolysis of (1->4)-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate
show the reaction diagram
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
condensation
-
-
hydrolysis of O-glycosyl bond
transglycosylation
-
-
PATHWAY
BRENDA Link
KEGG Link
MetaCyc Link
Glycosaminoglycan degradation
-
-
Metabolic pathways
-
-
SYSTEMATIC NAME
IUBMB Comments
hyaluronate 4-glycanohydrolase
Also hydrolyses 1,4-beta-D-glycosidic linkages between N-acetyl-galactosamine or N-acetylgalactosamine sulfate and glucuronic acid in chondroitin, chondroitin 4- and 6-sulfates, and dermatan.
CAS REGISTRY NUMBER
COMMENTARY hide
37326-33-3
-
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
buffalo
-
-
Manually annotated by BRENDA team
WormBase accession T22C8.2, cDNA: WBGene 00011923 (WormBase); strain N2
-
-
Manually annotated by BRENDA team
canine
-
-
Manually annotated by BRENDA team
goat
-
-
Manually annotated by BRENDA team
guinea pig
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
Eusimulium latipes
-
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
scorpion
-
-
Manually annotated by BRENDA team
funnel web spider
-
-
Manually annotated by BRENDA team
i.e. JSRV
-
-
Manually annotated by BRENDA team
6 isozymes in sperm
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
Norway lobster
-
-
Manually annotated by BRENDA team
Odagmia ornata
-
-
-
Manually annotated by BRENDA team
Ovis aries aries
ovine
-
-
Manually annotated by BRENDA team
Palamneus gravimanus
Indian black scorpion
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
2 isoforms
-
-
Manually annotated by BRENDA team
-
UniProt
Manually annotated by BRENDA team
synthetic construct
using the information of preferred Pichia pastoris codons as provided by Genscript, Inc., the native sequence is de novo synthesized to create a fully codon-optimized cDNA (Hya delta c) and the synthetic gene is expressed in Pichia
EU152302
Genbank
Manually annotated by BRENDA team
Vipera elegans
2 isoforms
-
-
Manually annotated by BRENDA team
-
SwissProt
Manually annotated by BRENDA team
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
physiological function
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
4-S-chondroitin sulfate + H2O
?
show the reaction diagram
6-S-chondroitin sulfate + H2O
?
show the reaction diagram
chitin + H2O
?
show the reaction diagram
chondroitin + H2O
?
show the reaction diagram
chondroitin + H2O
GlcAbeta(1-3)GalNAcbeta(1-4)GlcAbeta(1-3)GalNAc + ?
show the reaction diagram
chondroitin 4-sulfate + H2O
?
show the reaction diagram
chondroitin 6-sulfate + H2O
?
show the reaction diagram
chondroitin B sulfate + H2O
?
show the reaction diagram
very little hydrolase activity towards chondroitin sulfate B (dermatan sulfate)
-
-
?
chondroitin sulfate + H2O
?
show the reaction diagram
chondroitin sulfate A + H2O
?
show the reaction diagram
chondroitin sulfate A + H2O
oligosaccharides + ?
show the reaction diagram
chondroitin sulfate B + H2O
?
show the reaction diagram
chondroitin sulfate C + H2O
?
show the reaction diagram
chondroitin sulfate D + H2O
?
show the reaction diagram
chondroitin sulfate-rich proteoglycan + H2O
?
show the reaction diagram
Collagen + H2O
?
show the reaction diagram
-
-
-
?
dematan + H2O
?
show the reaction diagram
-
-
-
?
dermatan + H2O
?
show the reaction diagram
-
7% activity compared to sodium hyaluronate
-
-
?
hyaluronan + H2O
?
show the reaction diagram
hyaluronan + H2O
hexasaccharides + tetrasaccharides
show the reaction diagram
-
absolutely specific for
main products, with N-acetyl-beta-D-glucosamine at the reducing end, cleavage of beta-1,4-glycosidic linkage, not beta-1,3-glycosidic linkage
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
hyaluronan + H2O
N-acetylglucosamine + D-glucuronate
show the reaction diagram
-
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
oligosaccharides
show the reaction diagram
-
specific cleavage of beta-1,4-glucosidic linkages
-
?
hyaluronan + H2O
tetraoligosaccharides + hexaoligosaccharides
show the reaction diagram
hyaluronan + H2O
tetrasaccharides units of hyaluronan
show the reaction diagram
hyaluronan decasaccharide + H2O
hyaluronan tetrasaccharide + hyaluronan hexasaccharide + hyaluronan octasaccharide +
show the reaction diagram
-
-
31.5% hyaluronan tetrasaccharide, 48.3% hyaluronan hexasaccharide, 14.7% hyaluronan octasaccharide, 5.5% hyaluronan decasaccharide
-
?
hyaluronan octasaccharide + H2O
hyaluronan tetrasaccharide + hyaluronan hexasaccharide
show the reaction diagram
-
-
46.8% hyaluronan tetrasaccharide, 32.7% hyaluronan hexasaccharide, 20.5% hyaluronan octasaccharide. Enzyme generates a disaccharide intermediate from hyaluronan oligosaccharide, the majority of which is transferred to the nonreducing ends of other oligosaccharides, only traces being released as free disaccharide. When hyaluronan octasaccharide, with an unsaturated glucuronic acid at the nonreducing end, is used as a substrate, only a tetrasaccharide product is detected by HPLC. MS shows that the product is a mixture of equal amounts of two tetrasaccharides, one with and the other without the unsaturated glucuronic acid. This suggests that, in the case of substrates with a double bond at the nonreducing end, a tetrasaccharide is cleaved off instead of a disaccharide
-
?
hyaluronan oligosaccharides + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
specific cleavage of beta-1,4-glucosidic linkages
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
hyaluronate + H2O
oligosaccharides
show the reaction diagram
-
from human umbilical cord
establishing of a rapid, sensitive PAGE method for analysis of hyaluronan oligosaccharides
?
hyaluronic acid + H2O
?
show the reaction diagram
hyaluronic acid + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
-
-
-
?
hyaluronic acid + H2O
oligosaccharides + ?
show the reaction diagram
hyaluronic acid + H2O
tetraoligosaccharides + ?
show the reaction diagram
hyaluronic acid hexasaccharide + H2O
?
show the reaction diagram
-
not only lower oligosaccharides, but also higher oligosaccharides are produced, transglycosylation activity, multiple disaccharide units are rapidly transferred from one substrate molecule to another
-
-
r
hyaluronic acid hexasaccharide + H2O
octasaccharide + disaccharide + tetrasaccharide
show the reaction diagram
-
hydrolysis in disaccharide units, transglycosylation activity, smallest substrate
-
r
hyaluronic acid octasaccharosyl-pyridylaminoside + H2O
hexasaccharosyl-pyridylaminoside + ?
show the reaction diagram
-
smallest substrate, hydrolysis of even-numbered oligosaccharides with glucuronic acid at the non-reducing terminal by successive removal of disaccharide units from the non-reducing terminal
-
?
hyaluronic acid-rich cumulus matrix + H2O
?
show the reaction diagram
sodium hyaluronate + H2O
?
show the reaction diagram
-
100% activity
-
-
?
additional information
?
-
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
hyaluronan + H2O
?
show the reaction diagram
O43820, Q12794
complete degradation, absolutely specific for
-
?
hyaluronan + H2O
hyaluronan oligomers
show the reaction diagram
hyaluronan + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
hyaluronan + H2O
tetrasaccharides units of hyaluronan
show the reaction diagram
-
absolutely specific for
-
-
?
hyaluronate + H2O
N-acetyl-beta-D-glucosamine + D-glucuronate
show the reaction diagram
Q08169
-
-
?
hyaluronic acid + H2O
?
show the reaction diagram
hyaluronic acid-rich cumulus matrix + H2O
?
show the reaction diagram
-
investment of oocyte during sperm invasion
-
?
additional information
?
-
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
CaCl2
-
more effective activation than with NaCl
diphosphate
-
30% activation
MgCl2
-
more effective activation than with NaCl
NO3-
-
18% enhanced activity at 0.8 mM
additional information
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
-
-
(2S)-2-(3,4-dimethoxy-5-oxo-2,5-dihydrofuran-2-yl)-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(2S)-2-[3,4-bis(benzyloxy)-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
-
-
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
-
-
(5R)-3,4-bis(benzyloxy)-5-(1,2-dihydroxyethyl)furan-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(5R)-5-(1,2-dihydroxyethyl)-3,4-dimethoxyfuran-2(5H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
(7S)-7-(1,2-dihydroxyethyl)-2,3-dihydrofuro[3,4-b][1,4]dioxin-5(7H)-one
-
inactive at concentrations less than 13 mM, at pH 5.0
2-hydroxy-2-[(5R)-7-oxo-2,3,5,7-tetrahydrofuro[3,4-b][1,4]dioxin-5-yl]ethyl hexadecaneperoxoate
-
inactive at concentrations less than 0.2 mM, at pH 5.0
2-mercaptoethanol
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 2,2-dimethylpropaneperoxoate
-
inactive at concentrations less than 1.1 mM, at pH 5.0
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-(benzyloxy)hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 6-phenoxyhexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl benzenecarboperoxoate
-
33% inhibition at 1.43 mM
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [(1-prop-1-yn-1-ylpenta-1,2-dien-1-yl)oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
-
-
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl {[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy}ethaneperoxoate
-
-
3-(4-methylpiperazin-1-yl)-5-phenyl-1H-indole
-
0.05 mM, 23% inhibition in stains-all assay, pH 7.0
3-amino-6-chloro-N-(diaminomethylidene)-5-[ethyl(propan-2-yl)amino]pyrazine-2-carboxamide
-
-
6-palmitoyl-L-ascorbic acid
acetylated hyaluronic acid
-
-
-
Ag+
-
82% inhibition at 0.8 mM
ajmaline
-
-
apigenin
aristolochic acid
ascorbic acid palmitate
-
inhibition at pH 7: 99%, at pH 3.5: 99%
beta1,4-galacto-oligosaccharides
butylated hydroxytoluene
-
-
chlorogenic acid
-
-
chondroitin O-sulfate
Chondroitin sulfates
-
-
cimicifugic acid H
-
-
cimicifugic acid I
-
-
cimicifugic acid J
-
-
citrate
-
-
clinopodic acid C
-
-
clinopodic acid E
-
-
curcumin
cysteine
-
complete inhibition from 0.012-1.2 mg/ml
D-isoascorbic acid
-
-
decyl gallate
-
-
dehydroascorbic acid
-
weak inhibition
dermatan O-sulfate
dermatan sulfate
dexamethasone
-
-
Dextran
-
-
Dextran sulfate
-
-
-
dimethyl sulfoxide
-
-
disodium cromoglycate
-
-
flavone
-
-
fukinolic acid
-
-
fully O-sulfonated chondroitin sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00135 mg/ml
-
fully O-sulfonated dermatan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00133 mg/ml
-
fully O-sulfonated heparan sulfate
-
competitive and noncompetitive mode, 50% inhibition at 0.00128 mg/ml
-
fully O-sulfonated heparin
-
50% inhibition at 0.00114 mg/ml
-
fully O-sulfonated hyaluronan
-
50% inhibition at 0.00078 mg/ml
glutathione
glycyrrhizic acid
-
-
heparan O-sulfate
-
IC50 = 0.00128 mg/ml
-
heparan sulfate
heparin
heparin O-sulfate
-
IC50 = 0.00114 mg/ml, competitive and non-competitive inhibitory effects
-
heptyl gallate
-
-
hexyl gallate
-
-
hyaluronan O-sulfate
-
IC50 = 0.00078 mg/ml
hyaluronic acid
-
inhibitory at high concentrations (0.73 g/l)
indomethacin
isorhamnetin
-
51.04% inhibition at 0.2 mM
kaempferol
L-Arginine-HCl
-
8% residual activity at 1 mM
L-ascorbic acid
L-ascorbic acid decanoate
-
-
L-ascorbic acid dodecanoate
-
-
L-ascorbic acid tridecanoate
-
-
L-ascorbic acid undecanoate
-
-
L-cysteine
Palamneus gravimanus
-
-
lepidepyrone
-
-
lycopic acid A
-
-
lycopic acid B
-
-
N-(4,6-dimethylpyridin-2-yl)-(1-ethylindole-3-yl)acetamide
-
inhibition at pH 7: 3%, but at pH 3.5: 134% activation
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 37%, but at pH 3.5: 117% activation
N-(4-chlorobenzyl)-1-(4-fluorobenzyl)-1H-indole-3-carboxamide
N-(4-fluorobenzyl)-1-benzyl-1H-indole-2-carboxamide
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
inhibition at pH 7: 50%, but at pH 3.5: 120% activation
N-acetyl-L-cysteine
n-propyl gallate
-
-
nitrated hyaluronic acid
-
-
-
nonyl gallate
-
-
nordihydroguaiaretic acid
-
-
octyl 3,4-dihydroxybenzoate
-
-
octyl 3,5-dihydroxybenzoate
-
-
octyl gallate
-
-
partially sulfated neomycin
partially sulfated planteose
partially sulfated verbascose
polymer from gentisic acid
-
-
-
quercetin
quinol
-
irreversible inhibition
quinone
-
irreversible inhibition
reserpine
-
-
rosmarinic acid
-
-
schizotenuin A
-
-
serum protein
shomaside A
-
-
shomaside B
-
-
shomaside C
-
-
shomaside D
-
-
shomaside E
-
-
sorghum bran
-
the ability of ethanolic extracts of bran from six cultivated varieties of Sorghum bicolor to inhibit hyaluronidase activity in vitro is assessed. Each extract inhibits hyaluronidase activity with this order of potency: Sumac higher than Shanqui Red higher than Black higher than Mycogen higher than Fontanelle higher than White sorghum. Hyaluronidase inhibition correlate positively with total phenolic content and ferric reducing antioxidant power values for each bran extract. Inhibition is not only due to condensed tannins (proanthocyanidins) because the Black sorghum cultivar lacks condensed tannins but has abundant anthocyanins and other polyphenols
-
sulfated 2-hydroxyphenyl monolactobioside
-
IC50 is 0.025 mM
-
sulfated hydroquinone galactoside
Tannic acid
additional information
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
bovine serum albumin
bovine serum albumine
-
-
-
compound 48/80
-
-
cysteine
-
60% activation
EDTA
-
up to 24% enhanced activity
interleukin 1-beta
acts synergistically with TNF-alpha to increase gene expression and activity; acts synergistically with TNF-alpha to increase gene expression and activity; acts synergistically with TNF-alpha to increase gene expression and activity
-
lysozyme
-
lysozyme can enhance HAase activity over a wide pH range from 3 to 9. Lysozyme can compete with HAase to form complexes with yaluronan, HAase is catalytically active over this whole pH domain when LYS limits its complexation with HA, and either the pI of bovine testicular HAase is high or positive patches on the surface of HAase allow the formation of electrostatic HA-HAase complexes at high pH values
-
N-(4,6-dimethylpyridin-2-yl)-(1-ethylindole-3-yl)acetamide
-
acts as an inhibitor at pH 7 and at pH 3.5 activity is increased to 134%
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
-
acts as an inhibitor at pH 7 and at pH 3.5 activity is increased to 117%
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
-
acts as an inhibitor at pH 7 and at pH 3.5 activity is increased to 120%
TNF-alpha
acts synergistically with interleukin 1-beta to increase gene expression and activity; acts synergistically with interleukin 1-beta to increase gene expression and activity; acts synergistically with interleukin 1-beta to increase gene expression and activity
-
additional information
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.12
Chondroitin
-
apparent KM, substrate calculated as disaccharide
0.48
chondroitin sulfate
-
apparent KM, substrate calculated as disaccharide
0.66
chondroitin sulfate A
-
at pH 4.5 and 37C
2.16
chondroitin sulfate C
-
at pH 4.5 and 37C
0.5
chondroitin sulfate D
-
at pH 4.5 and 37C
-
0.038 - 0.367
hyaluronan
0.00091
hyaluronic acid
-
in 5 mM ammonium acetate, at 37C and pH 5.0
49.3
hyaluronic acid from Streptococcus pyogenes (35 kDa)
-
apparent KM, substrate calculated as disaccharide
-
additional information
hyaluronoic acid
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.082
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.112
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.251
(2R,3S)-2-(3,4-dihydroxybenzyl)-2-hydroxy-3-[[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.092
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(3-hydroxy-4-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.12
(2R,3S)-2-hydroxy-2-(4-hydroxybenzyl)-3-[[(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy]butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.153
(2R,3S)-3-[[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.138
(2R,3S)-3-[[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]oxy]-2-hydroxy-2-(4-hydroxybenzyl)butanedioic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.0285
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-21-cyclohexyl-28-hydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0264
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-23,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0193
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0364
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0556
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.052
(3beta,16alpha,21beta,22alpha)-16,22-bis(acetyloxy)-28-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0302
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0242
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[(2-methylbutanoyl)oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic aci
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.02
(3beta,16alpha,21beta,22alpha)-16,23,28-trihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosidur
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0552
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(2Z)-2-methylbut-2-enoyl]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0515
(3beta,16alpha,21beta,22alpha)-16,28-bis(acetyloxy)-22-hydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0449
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic a
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0405
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2E)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0368
(3beta,16alpha,21beta,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosi
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0297
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(2Z)-2-methylbut-2-enoyl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0387
(3beta,16alpha,21beta,22alpha)-22-(acetyloxy)-16,28-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0549
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-16,22-dihydroxy-21-[(3Z)-3-methyl-2-oxopent-3-en-1-yl]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0487
(3beta,16alpha,21beta,22alpha)-28-(acetyloxy)-21-cyclohexyl-16,22-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0241
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0249
(3beta,16alpha,22alpha)-16,28-dihydroxy-22-[[(2Z)-2-methylbut-2-enoyl]oxy]olean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0266
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,23,28-trihydroxyolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.0288
(3beta,16alpha,22alpha)-22-(cyclohexyloxy)-16,28-dihydroxy-23-oxoolean-12-en-3-yl beta-D-glucopyranosyl-(1->2)-[beta-D-xylopyranosyl-(1->2)-alpha-L-arabinopyranosyl-(1->3)]-beta-D-glucopyranosiduronic acid
Bos taurus
-
in 0.1 M acetate buffer (pH 4.0), at 37C
0.21
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl ([1-[2-(benzyloxy)ethenylidene]but-2-yn-1-yl]oxy)ethaneperoxoate
Bos taurus
-
at pH 5.0
0.105
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-phenoxyundecaneperoxoate
Bos taurus
-
at pH 5.0
0.037
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 11-[[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]undecaneperoxoate
Bos taurus
-
at pH 5.0
2.006
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl 3-(2-phenylethenylidene)hex-4-yneperoxoate
Bos taurus
-
at pH 5.0
1.38
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl decaneperoxoate
Bos taurus
-
at pH 5.0
0.208
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl dodecaneperoxoate
Bos taurus
-
at pH 5.0
0.057
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl hexadecaneperoxoate
Bos taurus
-
at pH 5.0
0.039
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl octadecaneperoxoate
Bos taurus
-
at pH 5.0
0.071
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tetradecaneperoxoate
Bos taurus
-
at pH 5.0
0.096
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl tridecaneperoxoate
Bos taurus
-
at pH 5.0
0.58
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl undecaneperoxoate
Bos taurus
-
at pH 5.0
0.188
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[1-(2-phenylethenylidene)but-2-yn-1-yl]oxy]ethaneperoxoate
Bos taurus
-
at pH 5.0
0.543
2-[(2R)-3,4-dihydroxy-5-oxo-2,5-dihydrofuran-2-yl]-2-hydroxyethyl [[2-(2-phenylethenylidene)pent-3-yn-1-yl]oxy]ethaneperoxoate
Bos taurus
-
at pH 5.0
0.008 - 0.018
ascorbic acid palmitate
0.525
cimicifugic acid H
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.143
cimicifugic acid I
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.193
cimicifugic acid J
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.0801
clinopodic acid C
Bos taurus
-
in 0.1 M acetate buffer, at 37C
0.0828
clinopodic acid E
Bos taurus
-
in 0.1 M acetate buffer, at 37C
0.057
curcumin
Naja naja
-
IC50 is 0.057 mM
0.58
decyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.45
disodium cromoglycate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.144
fukinolic acid
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.026
glycyrrhizic acid
Homo sapiens
-
at pH 3.5
0.112
heptyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.253
hexyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.086
indomethacin
Naja naja
-
IC50 is 0.086 mM
0.378
L-ascorbic acid decanoate
Homo sapiens
-
at pH 3.5
0.076
L-ascorbic acid dodecanoate
Homo sapiens
-
at pH 3.5
0.05
L-ascorbic acid tridecanoate
Homo sapiens
-
at pH 3.5
0.143
L-ascorbic acid undecanoate
Homo sapiens
-
at pH 3.5
3.3
lepidepyrone
Bos taurus
-
at 37C
0.134
lycopic acid A
Bos taurus
-
in 0.1 M acetate buffer, at 37C
0.141
lycopic acid B
Bos taurus
-
in 0.1 M acetate buffer, at 37C
0.078
N-(4,6-dimethylpyridin-2-yl)-[5-bromo-1-(4-methyl)indole-3-yl]carboxamide
Bos taurus
-
pH: 7.0
0.046
N-(pyridin-4yl)-[5-bromo-1-(4-fluorobenzyl)indole-3-yl]carboxamide
Bos taurus
-
pH: 7.0
4
N-acetyl-L-cysteine
Bos taurus
-
in 0.2 M sodium acetate buffer pH 5.5 containing 0.15 M NaCl at 37C
0.167
nonyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.902
octyl 3,4-dihydroxybenzoate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.113
octyl 3,5-dihydroxybenzoate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.106
octyl gallate
Bos taurus
-
in 0.1 M sodium acetate buffer, pH 4.0, at 37C
0.005 - 0.008
partially sulfated planteose
0.04
partially sulfated verbascose
Apis mellifera
-
2 forms, the non-sulfated verbascose is not inhibitory, IC50 are 0.040 mM and 0.003 mM
-
0.2401 - 0.545
rosmarinic acid
0.241
schizotenuin A
Bos taurus
-
in 0.1 M acetate buffer, at 37C
0.573
shomaside A
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.43
shomaside B
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.663
shomaside C
Bos taurus
-
in 0.1 mM acetate buffer (pH 3.5), at 37C
0.658
shomaside D
Bos taurus
-
IC50 above 0.658 mM, in 0.1 mM acetate buffer (pH 3.5), at 37C
0.79
shomaside E
Bos taurus
-
IC50 above 0.79 mM, in 0.1 mM acetate buffer (pH 3.5), at 37C
0.025
sulfated 2-hydroxyphenyl monolactobioside
Bos taurus
-
IC50 is 0.025 mM
-
0.006 - 0.015
sulfated hydroquinone galactoside
0.07
Tannic acid
Naja naja
-
IC50 is 0.070 mM
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.0000245
recombinant enzyme from crude extract, in 100 mM sodium phosphate, pH 5.0, at 37C
0.000239
recombiannt enzyme after 9.6fold purification, in 100 mM sodium phosphate, pH 5.0, at 37C
0.00184
-
venom gland extract, at 37C
0.03767
-
after 20.4fold purification, at 37C
0.08
pH 3.5, 37C
0.85
-
crude enzyme, at pH 3.8 and 27C
1.5
pH 7.1, 37C
1.55
pH 7.1, 37C
2.4
pH 3.5, 37C
7.47
Ovis aries aries
-
-
20.4
-
after 24fold purification, at pH 3.8 and 27C
22.6
pH 3.5, 37C
61.15
pH 3.5, 37C
6412
Palamneus gravimanus
-
turbidity reduction units/min/mg, purified enzyme
additional information